Frontier Biotechnologies Inc. (SHA:688221)
China flag China · Delayed Price · Currency is CNY
22.22
-0.20 (-0.89%)
At close: Jul 30, 2025, 2:57 PM CST

Frontier Biotechnologies Company Description

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patient health in China.

The company’s medicines address the unmet medical needs of patients in the areas of anti-HIV treatment and pain management.

It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products in development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints.

Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.

Frontier Biotechnologies Inc.
CountryChina
Founded2002
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees302
CEODong Xie

Contact Details

Address:
Building E-2, Green Window
Nanjing, 211199
China
Phone86 25 6964 8375
Websitefrontierbiotech.com

Stock Details

Ticker Symbol688221
ExchangeShanghai Stock Exchange
Fiscal YearJanuary - December
Reporting CurrencyCNY
SIC Code2836

Key Executives

NamePosition
Qi ShaoSenior Vice President, Chief Operating Officer and Chief Financial Officer
Dr. Rongjian Lu Ph.D.Chief Technology Officer and Director
Yuting ZhuSupervisor and Deputy GM Administrative Director
Hangzhou LvSenior Vice President of Marketing and Sales
Qianya GaoVice President, Deputy GM and Secretary of the Board of Directors
Dr. Dong Xie Ph.D.Founder, Chairman, President and Chief Scientific Officer
Xin GuanAccounting Supervisor
Dr. Changjin Wang Ph.D.MD, CBO and Director
Michael HuC.M.O.
Michael WangSenior Vice President and Head of Infectious Diseases Therapy Area